For fixed tissue samples, consultative services as well as immunohistochemical staining for glucagon, PGP9.5, synaptophysin and CAM5.2 (LMW) are available
General References
Chastain MA.The glucagonoma syndrome: a review of its features and discussion of new perspectives.Am J Med Sci. 2001;321(5):306-320. (Link to PubMed)
Cruz-Bautista I, Lerman I, Perez-Enriquez B, Padilla LS, Torres CL, Lopez A, Cabrera T, Mehta RP, Gomez-Perez FJ, Rull JA, Orozco-Topete R.Diagnostic challenge of glucagonoma: case report and literature review.Endocr Pract. 2006;12(4):422-426. (Link to PubMed)
Jabbour SA, Davidovici BB, Wolf R.Rare syndromes.Clin Dermatol. 2006;24(4):299-316. (Link to PubMed)
Oberg K, Eriksson B.Endocrine tumours of the pancreas.Best Pract Res Clin Gastroenterol. 2005;19(5):753-781. (Link to PubMed)
Soga J, Yakuwa Y.Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases.J Hepatobiliary Pancreat Surg. 1998;5(3):312-319. (Link to PubMed)
Tierney EP, Badger J.Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.MedGenMed. 2004;6(3):4-. (Link to PubMed)
van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR.The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.Eur J Endocrinol. 2004;151(5):531-537. (Link to PubMed)
Reviewed by
Meikle, A. Wayne, M.D. Medical Director, RIA and Endocrinology at ARUP Laboratories; Professor of Internal Medicine and Pathology, University of Utah
Comprehensive Review: July 2008
Last Update: July 2008